Table 1.

Reported Cases Harboring ERBB3 Mutations Treated with Targeted Therapy

Tumor Type	ERBB3 Mutation	Treatment	Treatment Line	Response	PFS	Ref.
Rectal neuroendocrine tumor	V104L	Trastuzumab with Lapatinib	Third-line	SD	51 days	[22]
Breast cancer	G284R	Trastuzumab with Lapatinib	Third-line	PR	40 weeks	[27]
Biliary tract carcinoma	–	Trastuzumab with Lapatinib	–	PR	–	[32]
Metastatic urothelial cancer	V104M	Afatinib	–	SD	6.3 months	[31]
Metastatic urothelial cancer	G284R	Afatinib	–	SD	7 months	[31]

Abbreviations: PR, partial response; PFS, progression-free survival; SD, stable disease.